JMJD1C

Across TCGA pan-cancer cohorts, JMJD1C mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JMJD1C data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher JMJD1C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated JMJD1C expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where JMJD1C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.305	0.558	.001	42	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	28	view →
GBM	OS	Tertile	All	0.581	0.268	.003	12	view →
LSCC	DFS	Tertile	II,III,IV	0.845	1.000	.009	7	view →
LUAD	DFS	Quartile	II,III,IV	0.421	0.744	.022	3	view →
HNSC	OS	Tertile	III,IV	0.339	1.000	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JMJD1C–PDAC (DFS)

Open the PDAC breakdown →